Pyrazole compounds as modulators of FSHR and uses thereof

1. A method for treating a FSHR-mediated disorder in a subject in need thereof, comprising the step of administering to said subject a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

X is O;

Y is O;

Z is N;

each R is independently hydrogen, C 1-6 aliphatic, aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted; or

two R groups on the same atom are taken together with the atom to which they are attached to form an aryl ring, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;

Ring A is phenyl;

R 1 is —OR;

R 2 is aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of which is optionally substituted;

R 3 is an optionally substituted phenyl;

each R 4 is independently —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO 2 , —SO 2 R, —SOR, —C(O)R, —CO 2 R, —C(O)N(R) 2 , —NRC(O)R, —NRC(O)N(R) 2 , —NRSO 2 R, or —N(R) 2 ;

R 5 is an optionally substituted C 1-6 aliphatic; and

R 6 is an optionally substituted C 1-6 aliphatic;

or R 5 , R 6 , and Z together form an optionally substituted 3-8 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

n is 0; and

p is 1.

2. The method of claim 1 , wherein R 2 is a 6-membered aryl ring, a 3-membered carbocyclic ring, or a 5-6 membered monocyclic heteroaryl ring having 1-4 nitrogen atoms, each of which is optionally substituted.

3. The method of claim 2 , wherein R 2 is

4. The method of claim 1 , wherein R 3 is

5. The method of claim 1 , wherein R 5 is methyl, t-butyl,

6. The method of claim 1 , wherein R 6 is methyl, ethyl, or t-butyl.

7. The method of claim 1 , wherein the compound of Formula I is a compound of formula I-e:

or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 , wherein the compound is selected from

or a pharmaceutically acceptable salt thereof.

9. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

10. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

11. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

12. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

13. The method of claim 1 , wherein the compound modulates FSHR activity.

14. The method of claim 1 , wherein the administration of the compound stimulates follicular development in the subject.

15. The method of claim 1 , wherein the FSHR-mediated disorder is selected from hypogonadotropic hypogonadism, isolated idiopathic hypogonadotropic hypogonadism, Kallmann syndrome, idiopathic hypogonadotropic hypogonadism, craniopharyngioma, combined pituitary hormone deficiency, fertile eunuch syndrome, mass lesion, pituitary adenoma, cyst, metastatic cancer to the sella, infiltrative lesion, hemochromatosis, sarcoidosis, histiocytosis, lymphoma, lymphocytic hypophysitis, meningitis, pituitary apoplexy, hyperprolactinemia, hypothyroidism, intentional secondary hypogonadism, pituitary infarction, sheehan syndrome, anorexia nervosa, congenital adrenal hyperplasia, or a disorder related to GnRH deficiency.